Multiparticulates Webinar Series Part III: Multiparticulates From Matrix Core Pellets – Glatt MicroPx And ProCell Technology
Thursday, 10 September 2020 – 03:00 PM CEST
Multiparticulates such as micropellets, pellets, granules and mini-tablets represent modern and innovative technology platforms. Multiparticulates can provide a number of advantages compared with larger-sized monolithic forms such as tablets. Increasing compliance is achieved for children – from birth to adolescence – and elderly. Individually tailored drug release profiles for any API and site specific drug delivery allow for an optimized and safe therapeutic effect.
Learn more about the innovative continuous technologies for matrix pellets in this live webcast held by Dr. Norbert Pöllinger, Head of Technology Development at Glatt. Pharmaceutical Services
Speaker:
Norbert Poellinger is heading the Technology Department unit. Until 2018, he was responsible for Development and Manufacturing Services Group at Glatt Pharmaceutical Services which included Pharmaceutical Development, Manufacturing, Quality Control, Quality Assurance and Plant Engineering. He studied pharmaceutical sciences at the University of Erlangen, Germany and received a PhD degree in Pharmaceutical Technology. Currently, the recently formed Glatt Pharmaceutical Services GmbH & Co.KG focuses on controlled release and taste masked multiparticulates including minitablets and tablets. Drug products for the paediatric and geriatric population are of particular interest. Logistic services have become a new service opportunity of Glatt.
Find all other webinars of the Mulitparticulates Series in our Webinar overview page